Antibody therapy for Alzheimer's disease.
The economic, social and emotional impact of Alzheimer's dementia is increasing dramatically as greater numbers live to advanced ages. The dearth of effective therapies has led to innovative approaches to treat the disease. This review summarizes the rationale, progress and setbacks regarding the use of antibody-based therapies to treat Alzheimer's disease and discusses future directions for this approach in Alzheimer's and other disorders.
Morgan
Dave
D
Dept of Pharmacology, University of South Florida, Tampa, FC 33612-4799, USA. dmorgan@hsc.usf.edu
D000544:Alzheimer Disease / Q000276:immunology / Q000628:therapy*; D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides / Q000097:blood / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000918:Antibody Specificity; D000936:Antigen-Antibody Complex / Q000097:blood; D000937:Antigen-Antibody Reactions; D002543:Cerebral Hemorrhage / Q000209:etiology; D002986:Clinical Trials as Topic; D018450:Disease Progression; D000939:Epitopes / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D051379:Mice; D008822:Mice, Transgenic; D017628:Microglia / Q000502:physiology; D010446:Peptide Fragments / Q000276:immunology; D017634:Self Tolerance; D014611:Vaccination
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D000939:Epitopes; D010446:Peptide Fragments